(Q35684517)

9 August 2017

title

A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study (English)

1 reference

9 August 2017

main subject

phase I clinical trial

0 references

1 reference

1

Maryam Fouladi

1 reference

9 August 2017

13

Susan M Blaney

1 reference

9 August 2017

10

Peter Houghton

1 reference

9 August 2017

John P Perentesis

2

1 reference

9 August 2017

Christine L Phillips

3

1 reference

9 August 2017

Sarah Leary

4

1 reference

9 August 2017

Joel M Reid

5

1 reference

9 August 2017

Renee M McGovern

6

1 reference

9 August 2017

Ashish M Ingle

7

1 reference

9 August 2017

Charlotte H Ahern

8

1 reference

9 August 2017

Matthew M Ames

9

1 reference

9 August 2017

L Austin Doyle

11

1 reference

9 August 2017

Brenda Weigel

12

1 reference

9 August 2017

language of work or name

1 reference

24 March 2014

1 reference

9 August 2017

published in

Pediatric Blood & Cancer

1 reference

9 August 2017

volume

61

1 reference

9 August 2017

issue

7

1 reference

9 August 2017

page(s)

1246-1251

1 reference

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Targeting the phosphoinositide 3-kinase pathway in cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Activation of Akt predicts poor outcome in neuroblastoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4456022

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival

12 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPBC.25023

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPBC.25023

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24664955

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24664955

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PBC.25023

1 reference

9 August 2017

1 reference

9 August 2017

1 reference